BioArctic AB (publ) (0RV2.IL)
IOB · SEK · Healthcare · Biotechnology
SEK 306.90 (-0.07%) as of
Key statistics
- Market cap
- 30.70B
- P/E (TTM)
- 99.97
- EPS (TTM)
- 3.07
- 52-week range
- 258.80 – 364.40
- Beta
- -0.23
- Revenue (TTM)
- 620.28M
- Profit margin
- 43.60%
- Volume
- 1.26k
About BioArctic AB (publ)
BioArctic AB (publ) develops biological drugs for patients with neurodegenerative disorders in Sweden. The company develops Lecanemab, Lecanemab AHEAD 3-45, and Lecanemab Back-up for the treatment of Alzheimer's disease. It also develops ABBV-0805, for treating Parkinson's disease. In addition, the company develops AD-BT2802 and AD-BT2803 drug projects against Alzheimer's disease that are being combined with blood-brain barrier technology and Brain Transporter to promote uptake of antibodies into the brain, as well as focuses on developing ND3014 antibodies for treating neurodegenerative disorders. Further, it develops BAN1503, AD-BT2802, AD-BT2803, AD1502, AD1503, and AD2603 for the treatment of Alzheimer's disease; ND-BT3814 andGD-BT6822 for the treatment of neurodegenerative disease; and PD1601, BAN0805, PD-BT2238, and PD1602 for the treatment of Parkinson's disease. It has research collaboration agreement with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Stockholm, Sweden
- Employees
- 75
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.